T1	Participants 73 132	patients with recurrent or metastatic head and neck cancer:
T2	Participants 225 301	Recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN)
T3	Participants 610 894	patients with recurrent or metastatic SCCHN and no prior systemic therapy for metastatic disease were randomized to pemetrexed (500 mg/m(2) ) plus cisplatin (75 mg/m(2) ; n = 398) or placebo plus cisplatin (75 mg/m(2) ; n = 397) to assess overall survival (OS) and secondary endpoints
